On the other hand, given the higher expression of these isoforms in cerebellum and the diminished vulnerability of this area to tau lesions in AD, it is tempting to establish a role for such isoforms as aggregation inhibitors in vivo [45]. Here, MAPT is linked to Alzheimer disease.